View Older Stories View More Recent Stories

Nov 3, 2016 09:09AM BioLineRx (BLRX) Reports Positive Phase 2a Correlative Data and Detailed Mechanism-of-Action Data for BL-8040
Nov 3, 2016 09:00AM BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Oct 5, 2016 07:04AM BioLineRx (BLRX) BL-8040 Data Accepted for ASH Presentation
Oct 5, 2016 07:00AM BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting
Sep 23, 2016 12:52PM Unusual 11 Mid-Day Movers 9/23: (IMPV) (BLRX) (TWTR) Higher; (ENPH) (APPS) (RAVE) Lower
Sep 23, 2016 07:01AM BioLineRx (BLRX) Enters ESLD in-Licensing Agreement
Sep 23, 2016 07:00AM BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Sep 22, 2016 09:07AM BioLineRx (BLRX) Updates on Corp. Objectives; Plans Ramp-up of Several BL-8040 Combo Phase 1bs
Sep 22, 2016 09:00AM BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY
Sep 20, 2016 07:03AM BioLineRx (BLRX) Commences BL-8040 Combo Phase 2a in Pancreatic Cancer
Sep 20, 2016 07:00AM BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
Sep 9, 2016 07:00AM BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York
Sep 8, 2016 07:01AM BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML
Sep 8, 2016 07:00AM BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
Sep 7, 2016 07:03AM BioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab
Sep 7, 2016 07:00AM BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
Aug 29, 2016 07:00AM BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 25, 2016 07:02AM BioLineRx (BLRX), I-Bridge Capital Form New JV in China
Aug 25, 2016 07:00AM BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
Aug 11, 2016 07:15AM BioLineRx Reports Second Quarter 2016 Financial Results
Aug 11, 2016 06:47AM BioLineRx (BLRX) Appoints New CEO
Aug 11, 2016 06:45AM BioLineRx Names Philip A. Serlin as Chief Executive Officer
Aug 8, 2016 07:00AM BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Aug 4, 2016 07:00AM BioLineRx to Report Second Quarter Results on August 11, 2016
Aug 1, 2016 07:00AM BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
Jun 28, 2016 07:11AM BioLineRx (BLRX) Submits Regulatory Filings Needed to Commence BL-8040 Combo Phase 2a in Pancreatic Cancer
Jun 28, 2016 07:00AM BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
Jun 15, 2016 07:00AM BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
May 19, 2016 07:00AM BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
May 17, 2016 08:04AM BioLineRx Reports First Quarter 2016 Financial Results
May 16, 2016 07:04AM BioLineRx (BLRX) Enters Framework Collaboration Agreement with MaRS Innovation
May 16, 2016 07:00AM BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
May 10, 2016 08:00AM BioLineRx to Report First Quarter 2016 Results on May 17, 2016
Apr 19, 2016 09:15AM BioLineRx (BLRX) Presents Underlying Mechanism of Action Data for BL-8040 at AACR 2016
Apr 19, 2016 08:00AM BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
Apr 4, 2016 07:03AM BioLineRx (BLRX) Announces CE Mark for BL-5010 as Treatment for Non-Surgical Removal of Skin Lesions
Apr 4, 2016 07:00AM BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
Mar 29, 2016 07:03AM BioLineRx (BLRX) Reports Successful Top-Line Results in Phase 2 Trial for AML
Mar 29, 2016 07:00AM BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
Mar 23, 2016 07:01AM BioLineRx (BLRX) Begins BL-8040 Phase 2 as Novel Stem Cell Mobilization Treatment
Mar 23, 2016 07:00AM BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Nov 3, 2014 12:09PM Streetinsider.com's Hot Lunchtime Reads 11/3: (TWTR) (ZAGG) (UNH) (CLF) (BLRX)
View More Recent Stories View Older Stories